0.7081
price down icon10.05%   -0.0791
after-market Dopo l'orario di chiusura: .74 0.0319 +4.51%
loading
Precedente Chiudi:
$0.7872
Aprire:
$0.7361
Volume 24 ore:
154.34K
Relative Volume:
0.62
Capitalizzazione di mercato:
$39.05M
Reddito:
-
Utile/perdita netta:
$-131.52M
Rapporto P/E:
-0.3978
EPS:
-1.78
Flusso di cassa netto:
$-107.56M
1 W Prestazione:
+3.86%
1M Prestazione:
+3.52%
6M Prestazione:
-62.53%
1 anno Prestazione:
-85.00%
Intervallo 1D:
Value
$0.7081
$0.76
Intervallo di 1 settimana:
Value
$0.7081
$0.87
Portata 52W:
Value
$0.63
$6.80

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Name
Nome
Prelude Therapeutics Inc
Name
Telefono
(302) 467-1280
Name
Indirizzo
175 INNOVATION BOULEVARD, WILMINGTON
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
PRLD's Discussions on Twitter

Confronta PRLD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PRLD
Prelude Therapeutics Inc
0.7081 39.05M 0 -131.52M -107.56M -1.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-09-19 Aggiornamento H.C. Wainwright Neutral → Buy
2024-06-20 Downgrade Barclays Equal Weight → Underweight
2024-03-13 Iniziato JMP Securities Mkt Outperform
2024-02-20 Downgrade H.C. Wainwright Buy → Neutral
2023-12-19 Downgrade Morgan Stanley Equal-Weight → Underweight
2022-11-21 Downgrade BofA Securities Neutral → Underperform
2022-09-09 Downgrade Morgan Stanley Overweight → Equal-Weight
2022-07-29 Iniziato Jefferies Buy
2022-03-15 Downgrade BofA Securities Buy → Neutral
2022-02-28 Downgrade Barclays Overweight → Equal Weight
2021-10-08 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2021-07-27 Aggiornamento BofA Securities Neutral → Buy
2021-04-26 Iniziato H.C. Wainwright Buy
2021-03-09 Iniziato Barclays Overweight
2020-11-20 Downgrade BofA Securities Buy → Neutral
2020-10-20 Iniziato BofA Securities Buy
2020-10-20 Iniziato Goldman Neutral
2020-10-20 Iniziato Morgan Stanley Equal-Weight
Mostra tutto

Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie

pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 16,049 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Prelude Therapeutics reports preclinical profile of first-in-human SMARCA2 degrader - BioWorld MedTech

Apr 01, 2025
pulisher
Mar 29, 2025

Prelude Therapeutics Founder Acquires 28% More Stock - Yahoo Finance

Mar 29, 2025
pulisher
Mar 28, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 28, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics stock surges on insider buying - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics stock surges on insider buying By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics chief chemistry officer acquires $69,250 in stock By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics chief chemistry officer acquires $69,250 in stock - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 25, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock - Investing.com India

Mar 25, 2025
pulisher
Mar 24, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock By Investing.com - Investing.com Australia

Mar 24, 2025
pulisher
Mar 19, 2025

Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 17, 2025

Prelude Therapeutics’ SWOT analysis: biotech stock faces mixed outlook amid clinical trials - Investing.com Australia

Mar 17, 2025
pulisher
Mar 16, 2025

NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial - MyChesCo

Mar 16, 2025
pulisher
Mar 14, 2025

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Mar 14, 2025
pulisher
Mar 14, 2025

Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares By Investing.com - Investing.com South Africa

Mar 14, 2025
pulisher
Mar 14, 2025

Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares - Investing.com

Mar 14, 2025
pulisher
Mar 13, 2025

Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements - MyChesCo

Mar 13, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Purchases 154,826 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

Prelude Therapeutics Reports 2024 Financial Results - TipRanks

Mar 11, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 10, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77) - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics Inc SEC 10-K Report - TradingView

Mar 10, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 - GlobeNewswire

Mar 10, 2025
pulisher
Mar 10, 2025

PRLDPrelude Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Mar 10, 2025
pulisher
Mar 09, 2025

Mineralys Therapeutics to Announce Pivotal Trial Results for Lorundrostat - MyChesCo

Mar 09, 2025
pulisher
Mar 07, 2025

Enovis Corporation Announces Participation in Upcoming Investor Conferences - MyChesCo

Mar 07, 2025
pulisher
Mar 06, 2025

Prelude Therapeutics to Present at Barclays Global Healthcare Conference - MSN

Mar 06, 2025
pulisher
Mar 05, 2025

Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MyChesCo

Mar 05, 2025
pulisher
Mar 05, 2025

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

How Will Prelude's Cancer Pipeline Updates Impact Investors at Upcoming Barclays Conference? - StockTitan

Mar 05, 2025
pulisher
Mar 05, 2025

Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MyChesCo

Mar 05, 2025
pulisher
Mar 04, 2025

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully - Yahoo Finance

Mar 04, 2025
pulisher
Feb 28, 2025

Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 - MSN

Feb 28, 2025
pulisher
Feb 27, 2025

PRLD stock touches 52-week low at $0.79 amid market challenges - Investing.com

Feb 27, 2025
pulisher
Feb 26, 2025

Palvella Therapeutics to Present at TD Cowen 45th Annual Healthcare Conference - MyChesCo

Feb 26, 2025
pulisher
Feb 25, 2025

Context Therapeutics Grants Stock Options to New Employees - MyChesCo

Feb 25, 2025
pulisher
Feb 18, 2025

Windtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq Compliance - MyChesCo

Feb 18, 2025
pulisher
Feb 13, 2025

Mineralys Therapeutics Delivers Financial Update and Advances Pipeline for Lorundrostat - MyChesCo

Feb 13, 2025
pulisher
Feb 13, 2025

Prelude Therapeutics (PRLD) to Release Quarterly Earnings on Thursday - Defense World

Feb 13, 2025
pulisher
Feb 12, 2025

Delaware weekly roundup: The Eagles’ River; CAFE opens apps; Prelude Therapeutics hires CFO - Technical.ly

Feb 12, 2025
pulisher
Feb 11, 2025

Akoya Biosciences Inc (AKYA)’s Day in Review: Closing at 2.34, Down by -4.88 - The Dwinnex

Feb 11, 2025
pulisher
Feb 11, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Feb 11, 2025
pulisher
Feb 07, 2025

Mineralys Therapeutics to Announce Q4 and Full-Year 2024 Financial Results - MyChesCo

Feb 07, 2025
pulisher
Feb 05, 2025

Prelude Therapeutics Names Bryant Lim As Permanent CFO -February 05, 2025 at 06:35 pm EST - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

Prelude Therapeutics Appoints Bryant D. Lim as CFO - TipRanks

Feb 05, 2025

Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Capitalizzazione:     |  Volume (24 ore):